Search

Search Constraints

You searched for: Author/Creator Bodei, Lisa

Search Results

1. 177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Issue 12 (December 2021)

2. A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management. Issue 5 (September 2016)

3. ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy. (June 2022)

8. ENETS standardized (synoptic) reporting for molecular imaging studies in neuroendocrine tumours. (20th October 2021)